Publications by authors named "B J Daugherty"
Article Synopsis
- The MOUD Hub is a new, user-friendly website aimed at improving access to medications for opioid use disorder (MOUD) by providing reliable information and resources.
- The study will assess the safety, acceptability, and feasibility of the Hub through focus groups with individuals who have lived experience with opioid use disorder and potential users.
- The website is set to launch in January 2025, with plans to promote it on Google and Reddit to reach a broader audience and analyze user engagement.
Article Synopsis
- PMN-MDSCs are dysfunctional immune cells that hinder the effectiveness of cancer immunotherapy, particularly by affecting the immune response in gastric cancer.
- The study developed a fusion protein, TFF2-MSA, that acts as a partial agonist for the CXCR4 receptor, enhancing the effects of anti-PD-1 therapy to reduce tumor growth and improve survival in various gastric cancer models.
- TFF2-MSA specifically reduces harmful PMN-MDSCs while keeping helpful neutrophils intact, which boosts the CD8 T cell-mediated anti-tumor response, contrasting with traditional CXCR4 antagonism that did not show similar benefits.
Convalescent sera, rich in pathogen-specific antibodies, offers passive immunity to patients with infectious diseases. Screening assays using convalescent sera are crucial for evaluating therapeutic efficacy, selecting suitable serum donors, and standardizing assays. They measure antibody levels, neutralizing potential, and specificity against viruses like SARS-CoV-2, ensuring therapeutic serum contains potent antibodies.
View Article and Find Full Text PDFArticle Synopsis
- There's growing interest in occupational therapy doctoral capstones focused on individuals experiencing homelessness due to the complexity of issues they face.
- The authors advocate for creating guidelines to ensure that these capstones are conducted ethically and effectively in unhoused settings.
- The column provides background information, reasons for the guidelines, and preliminary recommendations to encourage reflection and dialogue among students, faculty, and community agencies.
TNX-1800 is a synthetically derived live recombinant chimeric horsepox virus (rcHPXV) vaccine candidate expressing Wuhan SARS-CoV-2 spike (S) protein. The primary objective of this study was to evaluate the immunogenicity and efficacy of TNX-1800 in two nonhuman primate species challenged with USA-WA1/2020 SARS-CoV-2. TNX-1800 vaccination was well tolerated with no serious adverse events or significant changes in clinical parameters.
View Article and Find Full Text PDF